August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Hagop Kantarjian: Impact of MRD clearance kinetics in patients with AML undergoing intensive chemotherapy
Feb 19, 2025, 10:20

Hagop Kantarjian: Impact of MRD clearance kinetics in patients with AML undergoing intensive chemotherapy

Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, posted on X about recent paper by Wei-Ying Jen et al., titled “Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy” published on Blood Advances.

Authors: Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Sa A. Wang, Wei Wang, Sanam Loghavi, Naval G. Daver, Courtney D. DiNardo, Ghayas C. Issa, Hussein A. Abbas, Cedric Nasnas, Alex Bataller, Samuel Urrutia, Omer S. Karrar, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short

Hagop Kantarjian: Impact of MRD clearance kinetics in patients with AML undergoing intensive chemotherapy

Early attainment of undetectable MRD by MFC is independently associated with improved RFS in newly diagnosed AML. Intermediate risk pts who attain undetectable MRD should still undergo consolidative allo-SCT.”

Hagop Kantarjian: Impact of MRD clearance kinetics in patients with AML undergoing intensive chemotherapy